A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Pond, Gregory R ^a   Agarwal, Neeraj ^b   Bellmunt, Joaquim ^c   Choueiri, Toni K ^d   Qu, Angela ^e   Fougeray, Ronan ^e   Vaughn, David ^f   James, Nicholas D ^g   Salhi, Yacine ^e   Albers, Peter ^h   Niegisch, Günter ^h   Galsky, Matthew D ⁱ   Wong, Yu Ning ^j   Ko, Yoo Joung ^k   Stadler, Walter M ^l   O'Donnell, Peter H ^l   Sridhar, Srikala S ^m   Vogelzang, Nicholas J ⁿ   Necchi, Andrea ^o   Di Lorenzo, Giuseppe ^p   Sternberg, Cora N ^q   Mehta, Amitkumar ^r   Sonpavde, Guru ^r   more..

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d HARVARD MEDICAL SCHOOL   (United States)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^l SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ Department of Hematology Oncology   (United States)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^r University of Alabama at Birmingham   (United States)

more..

Author keywords

Advanced urothelial cancer; Nomogram; Progression free survival at 6 months; Response rate; Second line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; VANDETANIB; VINFLUNINE; VOLASERTIB;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; ADVANCED UROTHELIAL CANCER; AGED; DISEASE FREE SURVIVAL; LIVER TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; PROGRESSION-FREE SURVIVAL AT 6 MONTHS; RESPONSE RATE; SECOND-LINE THERAPY; URINARY TRACT CANCER;

ADVANCED UROTHELIAL CANCER; NOMOGRAM; PROGRESSION-FREE SURVIVAL AT 6 MONTHS; RESPONSE RATE; SECOND-LINE THERAPY;

AGED; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; UROLOGIC NEOPLASMS;

EID: 84898059092     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12564     Document Type: Article

References (25)

1. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11: 861-70
2. Beer TM, Goldman B, Nichols CR et al. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clin Genitourin Cancer 2008; 6: 36-9 (Pubitemid 351656242)
3. Choueiri TK, Ross RW, Jacobus S et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30: 507-12
4. Culine S, Theodore C, De Santis M et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94: 1395-401 (Pubitemid 43772272)
5. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2009; 105: 317-21
6. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-8 (Pubitemid 33136193)
7. Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115: 4110-7
8. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-61
9. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22: 288-94
10. Wong YN, Litwin S, Vaughn D et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012; 30: 3545-51
11. Ko YJ, Canil CM, Mukherjee SD et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013; 14: 769-76
12. Pili R, Qin R, Flynn PJ et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 2013; 11: 477-83
13. Sonpavde G, Pond GR, Fougeray R et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013; 63: 717-23
14. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-5
15. Sonpavde G, Maughan B, Boucher KM et al. External validation of the association of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in second-line therapy for advanced urothelial carcinoma. ESMO Congress, October 2012, abstract 1283
16. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265-70 (Pubitemid 46774696)
17. Stadler WM, Vaughn DJ, Sonpavde G et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer. J Clin Oncol 2011; 29 (Suppl.); abstr 4567
18. Harrell FE. rms: Regression Modeling Strategies. R package version 3.4-0. 2012. Available at: http://CRAN.R-project.org/package=rms. Accessed 1 May 2013
19. Mo Q, Gonen M, Heller G. CPE: Concordance Probability Estimates Survival Analysis. R package version 1.4.1. 2010. Available at: http://CRAN.R-project. org/package=CPE. Accessed 1 May 2013
20. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81 (Pubitemid 29470648)
21. Necchi A, Mariani L, Zaffaroni N et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012; 13: 810-6
22. Rosenberg JE, Halabi S, Sanford BL et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008; 19: 946-50 (Pubitemid 351627312)
23. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996; 156: 1606-8 (Pubitemid 26344001)
24. Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-5
25. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-40 (Pubitemid 34141835)